Mattias Mandorfer

Reply to: "Non selective beta blockers in cirrhosis".

HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure.

Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients.

Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis.

The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients.

Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin.

Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy.

Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis.

[MUW researcher of the month].

IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against Hepatitis C Virus genotype 1 or 4 in Caucasians.

Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting.

Revisiting liver disease progression in HIV/HCV-coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3.

New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension.

Reply: To PMID 24631577.

Response-guided boceprevir-based triple therapy in HIV/HCV-coinfected patients: the HIVCOBOC-RGT study.

PRO-C3-levels in patients with HIV/HCV-Co-infection reflect fibrosis stage and degree of portal hypertension.

Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites.

Evaluation of a new balloon occlusion catheter specifically designed for measurement of hepatic venous pressure gradient.

Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites.

Circulating miRNA-122 levels are associated with hepatic necroinflammation and portal hypertension in HIV/HCV coinfection.

Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy.

Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: A retrospective cohort study.

Performance of 2-D shear wave elastography in liver fibrosis assessment compared with serologic tests and transient elastography in clinical routine.

HCV targeting of patients with cirrhosis.

Association of CMV-Specific T Cell-Mediated Immunity with CMV DNAemia and Development of CMV Disease in HIV-1-Infected Individuals.

The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection.

Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure.

Conversion from Tacrolimus to Cyclosporine A Improves Glucose Tolerance in HCV-Positive Renal Transplant Recipients.

Advances in the management of HIV/HCV coinfection.

Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease.

Prognosis of cirrhotic patients with fungiascites and spontaneous fungal peritonitis (SFP).

Impact of Early Initiation of Antiretroviral Therapy in Patients with Acute HIV Infection in Vienna, Austria.

Plasma renin concentration represents an independent risk factor for mortality and is associated with liver dysfunction in patients with cirrhosis.

The trigger matters - outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites.

Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension.

Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study.

Nonselective beta blockers in patients with ascites: implications of a nationwide study.

HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe.

Prevention of progression from small to large varices: are we there yet? An updated meta-analysis.

Beta blockers and cirrhosis, 2016.

Beta adrenergic blockade and decompensated cirrhosis.

Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis.

Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna.

Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices.

Reply to: "Beta adrenergic blockade and advanced cirrhosis: Does it really improve survival in patients with acute-on-chronic liver failure?"

EV-Associated MMP9 in High-Grade Serous Ovarian Cancer Is Preferentially Localized to Annexin V-Binding EVs.

Effects of Portal Hypertension on Gadoxetic Acid-Enhanced Liver Magnetic Resonance: Diagnostic and Prognostic Implications.

Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients.

Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice.

Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).

ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis.

Role of diuretics in the harmful effects of beta blockers in patients with ascites. Author's reply.

Transferrin as a predictor of survival in cirrhosis.

Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding - A two decades experience.

Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension.

Monitoring the Evolution of Portal Hypertension After Sustained Virologic Response.

Heterozygosity for the alpha-1-antitrypsin Z allele in cirrhosis is associated with more advanced disease.

Pharmacological decrease of liver stiffness is pressure-related and predicts long-term clinical outcome.

Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function.

Liver disease in adults with α1-antitrypsin deficiency.

Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease.

Noninvasive Monitoring of Liver Disease Regression after Hepatitis C Eradication Using Gadoxetic Acid-Enhanced MRI.

Point Shear Wave Elastography for Non-invasive Assessment of Liver Fibrosis in Patients with Viral Hepatitis.

Editorial: surviving your genes-the role of PNPLA3 variation in end-stage liver disease. Authors' reply.

Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis.

Outcomes after placement of a SX-ELLA oesophageal stent for refractory variceal bleeding-A national multicentre study.

Small Esophageal Varices in Patients with Cirrhosis-Should We Treat Them?

The Renaissance of Cholemic Nephropathy: A Likely Underestimated Cause of Renal Dysfunction in Liver Disease.

Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information.

Inter- and intra-reader agreement for gadoxetic acid-enhanced MRI parameter readings in patients with chronic liver diseases.

Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension.

High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients.

Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication.

Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension.

Ascitic fluid polymorphic nuclear cell count impacts on outcome of cirrhotic patients with ascites.

Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma.

Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy.

Guideline-conform statin use reduces overall mortality in patients with compensated liver disease.

The value of different CT-based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis.

Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease.

Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease.

HCV-RNA is commonly detectable in rectal and nasal fluids of patients with high viremia.

Editorial: pressure to close the therapeutic window of non-selective beta blockers?

Dynamics of platelet count after sustained virologic response do not mirror those of hepatic venous pressure gradient.

Gut-liver axis signaling in portal hypertension.

The impact of hepatic steatosis on portal hypertension.

Does the Functional Liver Imaging Score Derived from Gadoxetic Acid-enhanced MRI Predict Outcomes in Chronic Liver Disease?

The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis.

Hepatic Steatosis in Lean Patients: Risk Factors and Impact on Mortality.

Portal hypertensive gastropathy is associated with iron deficiency anemia.

Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension.

Anemia and iron deficiency in compensated and decompensated cirrhosis: Prevalence and impact on clinical outcomes.

Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population.

The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease.

Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis.

Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease.

Author response to Letter to the Editor: 'AB0, von Willebrand factor/Factor VIII and portal vein thrombosis in decompensated cirrhosis: Too late to unmask the culprit?'